C12N 2710/24041
Use of virus, viral particle or viral elements as a vector
C12N2710/24041 (Use of virus, viral particle or viral elements as a vector) appears on 194 US grants and 210 published applications in this corpus.
Search patents in C12N- Granted patents
- 194
- Published applications
- 210
- Assignees
- 128
- Inventors
- 429
- Latest grant
- 2 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1992 | 1 | 0 |
| 1993 | 3 | 0 |
| 1994 | 9 | 0 |
| 1995 | 4 | 0 |
| 1996 | 4 | 0 |
| 1997 | 7 | 0 |
| 1998 | 16 | 0 |
| 1999 | 10 | 0 |
| 2000 | 8 | 0 |
| 2001 | 8 | 2 |
| 2002 | 7 | 2 |
| 2003 | 7 | 7 |
| 2004 | 1 | 16 |
| 2005 | 3 | 12 |
| 2006 | 3 | 10 |
| 2007 | 5 | 6 |
| 2008 | 4 | 9 |
| 2009 | 5 | 8 |
| 2010 | 4 | 8 |
| 2011 | 6 | 6 |
| 2012 | 1 | 5 |
| 2013 | 2 | 4 |
| 2014 | 2 | 5 |
| 2015 | 4 | 8 |
| 2016 | 4 | 15 |
| 2017 | 6 | 11 |
| 2018 | 10 | 9 |
| 2019 | 8 | 8 |
| 2020 | 7 | 14 |
| 2021 | 8 | 13 |
| 2022 | 6 | 10 |
| 2023 | 4 | 7 |
| 2024 | 8 | 11 |
| 2025 | 5 | 3 |
| 2026 | 4 | 1 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2710/24043Viral genome or elements thereof as genetic vectorIndexing code181
- C12N 2710/24044Chimeric viral vector comprising heterologous viral elements for production of another viralIndexing code4
- C12N 2710/24042Virus or viral particle as vehicleIndexing code2
- C12N 2710/24045Special targeting system for viral vectorsIndexing code1
Recent patents
- Compositions and methods for inducing an enhanced immune response using poxvirus vectors2 Jun 2026US 12,644,125 B2Bavarian Nordic A/S
- Oncolytic virus platform to treat hematological cancer10 Mar 2026US 12,569,526 B2Arizona Board of Regents on behalf of Arizona State University
- HBV vaccine13 Jan 2026US 12,521,431 B2Oxford University Innovation Limited
- Non-invasive agent applicator13 Jan 2026US 12,521,540 B2MuPharma Pty Ltd
- African swine fever virus vaccine4 Nov 2025US 12,458,690 B2Stichting Wageningen Research
- Personalized vaccine13 Aug 2026US 2026/0232778 A1Transgene S. A.
- Cancer therapies comprising a nuclear export inhibitor and an oncolytic virus7 Aug 2025US 2025/0249056 A1Arizona Board of Regents on behalf of Arizona State University
- Oncolytic virotherapy compositions and methods17 Apr 2025US 2025/0121017 A1UNM Rainforest Innovations
- Non-invasive agent applicator30 Jan 2025US 2025/0032766 A1MuPharma Pty Ltd
- Composition and methods including recombinant viruses modulating arginine biosynthesis26 Sep 2024US 2024/0316130 A1
Most cited
By later US patents
- NYVAC vaccinia virus recombinants comprising heterologous inserts137US 5,494,807 AVirogenetics Corporation · 1996
- Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence128US 5,833,975 AVirogenetics Corporation · 1998
- Porcine circoviruses vaccines diagnostic reagents105US 6,391,314 B1Merial Limited · 2002
- Porcine circovirus vaccine and diagnostics reagents99US 6,368,601 B1Merial Limited · 2002
- Pox virus containing DNA encoding a cytokine and/or a tumor associated antigen89US 6,265,189 B1Virogenetics Corporation · 2001